MEPRON
LOE ApproachingNDAORALTABLETPriority Review
Approved
Nov 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Priority Review
MEPRON by GSK is [see microbiology ()] . Approved for pneumocystis jirovecii pneumonia (pcp) in adults, adolescents (aged 13 years, older). First approved in 1992.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MEPRON is an oral small-molecule tablet approved in 1992 for treatment of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 and older. The mechanism of action involves inhibition of parasite microbiology pathways. It represents a foundational oral option in a narrow therapeutic indication with limited patient populations.
$0.322MPart D
LOE ApproachingDeclining
Mature product in late-stage lifecycle with minimal claims volume; brand team is likely small and focused on preservation rather than growth initiatives.
Mechanism of Action
[see Microbiology ()] .
Worked on MEPRON at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.